Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

被引：21
|
作者：
Felip, E. [1 ]
Crino, L. [2 ]
Kim, D. -W. [3 ]
Spigel, D. R. [4 ]
Nishio, M. [5 ]
Mok, T. [6 ]
Scagliotti, G. [7 ]
Cesic, D. [8 ]
Sutradhar, S. [9 ]
Shaw, A. T. [10 ]
机构：
[1] Vail dHebron Univ Hosp, Inst Oncol, Med Oncol Serv, Barcelona, Spain
[2] Osped S Maria Misericordia, Oncol Med, Perugia, Italy
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[4] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[5] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[7] Univ Turino, Oncol, Turin, Italy
[8] Novartis Pharmaceut, GMA Oncol, E Hanover, NJ USA
[9] Novartis Pharmaceut, GMA Biostat, E Hanover, NJ USA
[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30251-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141PD
引用
收藏
页码：S118 / S119
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK plus non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
    Cho, B. C. Chul
    Kim, D-W.
    Batra, U.
    Park, K.
    Kim, S-W.
    Yang, C. T.
    Jye, V. Pie
    Sriuranpong, V.
    Babu, K. G.
    Amin, K.
    Wang, Y.
    Wang, L.
    Bhering, M.
    Geater, S. Lucien
    ANNALS OF ONCOLOGY, 2020, 31 : S864 - S865
  • [32] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
    Gettinger, Scott N.
    Huber, Rudolf M.
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Hansen, Karin Holmskov
    Tiseo, Marcello
    Langer, Corey J.
    Paz-Ares, Luis G.
    West, Howard
    Reckamp, Karen L.
    Weiss, Glen J.
    Smit, Egbert F.
    Hochmair, Maximilian
    Kim, Sang-We
    Ahn, Myung-Ju
    Kim, Edward S.
    Groen, Harry J. M.
    Pye, Joanna
    Vranceanu, Florin
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK1) non-small cell lung cancer (NSCLC) patients (Pts)
    Reckamp, K. L.
    Lee, J.
    Huang, J.
    Proskorovsky, I.
    Reichmann, W.
    Krotneva, M.
    Kerstein, D.
    Huang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK plus NSCLC): Second interim analysis of ALCURE
    Mouri, A.
    Tsuda, T.
    Oki, M.
    Ichihara, E.
    Tanaka, H.
    Azuma, K.
    Arai, R.
    Kuyama, S.
    Akamatsu, H.
    Otsubo, K.
    Ajimizu, H.
    Matsumoto, M.
    Seto, Y.
    Uchibori, K.
    Hayashi, H.
    Miyauchi, E.
    Ishizuka, N.
    Kajihara, Y.
    Nakagawa, Y.
    Katayama, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1644 - S1645
  • [35] BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)
    Pan, X.
    Kwon, C. S.
    Garib, S. A.
    Forsythe, A.
    Lin, H. M.
    VALUE IN HEALTH, 2019, 22 : S439 - S439
  • [36] Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
    Kim, D.
    Tiseo, M.
    Ahn, M.
    Reckamp, K.
    Hansen, K. Holmskov
    Kim, S.
    Huber, R.
    West, H.
    Groen, H.
    Hochmair, M.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares Rodriguez, L.
    Smit, E.
    Reichmann, W.
    Kerstein, D.
    Haluska, F.
    Camidge, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
    Shaw, Alice T.
    Kim, Tae Min
    Crino, Lucio
    Gridelli, Cesare
    Kiura, Katsuyuki
    Liu, Geoffrey
    Novello, Silvia
    Bearz, Alessandra
    Gautschi, Oliver
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio
    Spigel, David R.
    Deudon, Stephanie
    Zheng, Cheng
    Pantano, Serafino
    Urban, Patrick
    Massacesi, Cristian
    Viraswami-Appanna, Kalyanee
    Felip, Enriqueta
    LANCET ONCOLOGY, 2017, 18 (07): : 874 - 886
  • [38] Outcomes Based On Brain Metastases Characteristics And Treatment Modality For Patients With EGFR-Mutated And ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC)
    Dutta, S. W.
    Mack, M. L.
    Ward, K. A.
    Aliotta, E.
    Hall, R.
    Gentzler, R. D.
    Sheehan, J. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E689 - E689
  • [39] Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
    Felip, Enriqueta
    de Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Thomas
    Liu, Geoffrey
    Lolkema, Martijn P.
    Selvaggi, Giovanni
    Giannone, Vanessa
    Cazorla, Pilar
    Baum, Jason
    Balbin, O. Alejandro
    Wang, Luojun
    Lau, Yvonne Y.
    Scott, Jeffrey W.
    Tan, Daniel Shao-Weng
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 392 - 403
  • [40] Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK plus Non-Small Cell Lung Cancer and Brain Metastases
    Wang, Shouzheng
    Xing, Puyuan
    Li, Junling
    Hao, Xuezhi
    Zhang, Tongtong
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S944 - S944
12345